BioAge Labs Inc. BIOA 深 沪
等待开盘 09-09 09:30:00 美东时间
5.09
+0.330
+6.93%
华盛通- 最 高5.09
- 今 开4.83
- 成交量 23.87万股
- 最 低 4.745
- 昨 收 4.76
- 总市值 1.82亿
- 52周最高 26.62
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 0.156
- 委 比 -74.67%
- 总股本 3585.00万
- 历史最高 26.62
- 量 比 0.68
- 振 幅 7.25%
- 历史最低 0.156
- 每 手 1
- 风险率 7.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioArctic Founders to Divest Minor Shareholdings
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update. BioArctic AB anno...
09-04 00:05
FDA Approves BioArctic’s Subcutaneous Alzheimer’s Treatment
An update from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. BioArcti...
08-30 06:02
Novartis and BioArctic sign collaboration and license deal
BioArctic AB (Nasdaq Stockholm: BIOA B) has announced a collaboration and licensing agreement with Novartis Pharma AG (NYSE:NVS) to explore a potential new treatment for neurodegenerative diseases. Th...
08-27 02:49
BioArctic Partners with Novartis for Neurodegeneration Treatment
The latest announcement is out from BioArctic AB Class B ( ($SE:BIOA.B) ). BioA...
08-26 13:32
BioArctic’s Leqembi Launches in EU, Targeting Alzheimer’s Disease
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement. BioArctic ...
08-25 15:34
BioAge Labs Announces First Participant Dosed In Phase 1 Clinical Trial Evaluating BGE-102, Orally Available Small Molecule NLRP3 Inhibitor For Treatment Of Obesity
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profileInitial development planned in obesity;
08-15 21:05
Bioage Labs Q2 EPS $(0.60) Misses $(0.45) Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.45) by 33.33 percent.
08-07 05:13
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, plans to host a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss its second-quarter 2025 financial results and business highlights. The webcast can be accessed at [this link](https://www.globenewswire.com/Tracker?data=RLJAQOCakPWTHB0UCPVd-O7q7MF8j9ZD5NrEL_6LnwrV...
08-04 12:00
BioArctic and Eisai to Present Lecanemab Data at AAIC 2025
An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. Bi...
07-22 14:33
BioArctic’s Alzheimer’s Drug Lecanemab Wins Prestigious Bioindustry Award
BioArctic AB Class B ( ($SE:BIOA.B) ) has issued an update. BioArctic AB’s part...
07-16 16:02
